b3 adrenergic stimulation restores nitric oxide/redox balance and enhances endothelial function in hyperglycemia

Journal of the American Heart Association

Volumn 5, Issue 2, 2016, Pages

  Galougahi, Keyvan Karimi ^b,c   Liu, Chia Chi ^a   Garcia, Alvaro ^a   Gentile, Carmine ^b,e   Fry, Natasha A ^a   Hamilton, Elisha J ^a   Hawkins, Clare L ^a,e   Figtree, Gemma A ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Medicine   (United States)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Endothelial dysfunction; Endothelial nitric oxide synthase; Hyperglycemia; Oxidative stress; 3 adrenergic receptors

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALLOXAN; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLUTAREDOXIN; GLUTAREDOXIN 1; INSULIN RECEPTOR; NITRIC OXIDE; POTASSIUM; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; S961; SODIUM; STREPTOZOCIN; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ANTIDIABETIC AGENT; BETA 3 ADRENERGIC RECEPTOR; DISODIUM (R,R)-5-(2-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)-AMINO)PROPYL)-1,3-BENZODIOXOLE-2,3-DICARBOXYLATE; GLUCOSE BLOOD LEVEL; GLUTATHIONE; PEPTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S961 PEPTIDE; SUPEROXIDE;

AGED; ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUTATHIONYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOPRECIPITATION; INSULIN BLOOD LEVEL; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN PROCESSING; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASCULAR DISEASE; VASODILATATION; ANIMAL; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RABBITS AND HARES; SIGNAL TRANSDUCTION; TIME FACTOR; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GLUTATHIONE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDES; RABBITS; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; SUPEROXIDES; TIME FACTORS;

EID: 85002990754     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002824     Document Type: Article

References (55)

1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070.
2. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today. 2006;11:524-533.
3. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation. 2006;114:1531-1544.
4. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res. 2012;111:1091-1106.
5. Majkova Z, Toborek M, Hennig B. The role of caveolae in endothelial cell dysfunction with a focus on nutrition and environmental toxicants. J Cell Mol Med. 2010;14:2359-2370.
6. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31:2741-2748.
7. Galougahi KK, Liu CC, Gentile C, Kok C, Nunez A, Garcia A, Fry NA, Davies MJ, Hawkins CL, Rasmussen HH, Figtree GA. Glutathionylation mediates angiotensin II-induced eNOS uncoupling, amplifying NADPH oxidase-dependent endothelial dysfunction. J Am Heart Assoc. 2014;3:e000731 doi: 10.1161/JAHA.113.000731.
8. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948-954.
9. Sato M, Hutchinson DS, Halls ML, Furness SG, Bengtsson T, Evans BA, Summers RJ. Interaction with caveolin-1 modulates G protein coupling of mouse beta3-adrenoceptor. J Biol Chem. 2012;287:20674-20688.
10. Bundgaard H, Liu C-C, Garcia A, Hamilton EJ, Huang Y, Chia KKM, Hunyor SN, Figtree GA, Rasmussen HH. b3 adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation. 2010;122:2699-2708.
11. Galougahi KK, Liu CC, Bundgaard H, Rasmussen HH. beta-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med. 2012;22:83-87.
12. Cai T, Wang H, Chen Y, Liu L, Gunning WT, Quintas LE, Xie ZJ. Regulation of caveolin-1 membrane trafficking by the Na/K-ATPase. J Cell Biol. 2008;182:1153-1169.
13. Gallogly MM, Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol. 2007;7:381-391.
14. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468:1115-1118.
15. Crabtree MJ, Brixey R, Batchelor H, Hale AB, Channon KM. Integrated redox sensor and effector functions for tetrahydrobiopterin-and glutathionylationdependent endothelial nitric-oxide synthase uncoupling. J Biol Chem. 2013;288:561-569.
16. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436-2443.
17. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904.
18. Schaffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R, Sturis J. A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun. 2008;376:380-383.
19. Audigane L, Kerfant B-G, El Harchi A, Lorenzen-Schmidt I, Toumaniantz G, Cantereau A, Potreau D, Charpentier F, Noireaud J, Gauthier C. Rabbit, a relevant model for the study of cardiac b3-adrenoceptors. Exp Physiol. 2009;94:400-411.
20. Kleschyov AL, Mollnau H, Oelze M, Meinertz T, Huang Y, Harrison DG, Munzel T. Spin trapping of vascular nitric oxide using colloid Fe(II)-diethyldithiocarbamate. Biochem Biophys Res Commun. 2000;275:672-677.
21. Zielonka J, Vasquez-Vivar J, Kalyanaraman B. Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine. Nat Protoc. 2008;3:8-21.
22. Webb RC, Bohr DF. Potassium-induced relaxation as an indicator of Na+-K+ ATPase activity in vascular smooth muscle. Blood Vessels. 1978;15:198-207.
23. Liu C-C, Karimi Galougahi K, Weisbrod RM, Hansen T, Ravaie R, Nunez A, Liu YB, Fry N, Garcia A, Hamilton EJ, Sweadner KJ, Cohen RA, Figtree GA. Oxidative inhibition of the vascular Na+-K+ pump via NADPH oxidase-dependent b1-subunit glutathionylation: implications for angiotensin II-induced vascular dysfunction. Free Radic Biol Med. 2013;65:563-572.
24. Figtree GA, Liu CC, Bibert S, Hamilton EJ, Garcia A, White CN, Chia KKM, Cornelius F, Geering K, Rasmussen HH. Reversible oxidative modification: a key mechanism of Na+-K+ pump regulation. Circ Res. 2009;105:185-193.
25. Karimi Galougahi K, Liu CC, Garcia A, Fry NA, Hamilton EJ, Figtree GA, Rasmussen HH. beta3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade. Am J Physiol Cell Physiol. 2015;309:C286-C295.
26. Gallogly MM, Starke DW, Mieyal JJ. Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid Redox Signal. 2009;11:1059-1081.
27. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979-1987.
28. Watts VL, Sepulveda FM, Cingolani OH, Ho AS, Niu X, Kim R, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Rameau G, O'Rourke B, Kass DA, Barouch LA. Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. J Mol Cell Cardiol. 2013;62:8-17.
29. Chakrabarti S, Chan CK, Jiang Y, Davidge ST. Neuronal nitric oxide synthase regulates endothelial inflammation. J Leukoc Biol. 2012;91:947-956.
30. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009;2:454-466.
31. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:537-546.
32. Sakurai K, Katoh M, Fujimoto Y. Alloxan-induced mitochondrial permeability transition triggered by calcium, thiol oxidation, and matrix ATP. J Biol Chem. 2001;276:26942-26946.
33. Black SM. b3-Adrenoceptor, glutathionylation, and diabetic cardiomyopathy. Focus on "beta3 adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade". Am J Physiol Cell Physiol. 2015;309:C283-285.
34. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a doubleedged sword in redox signalling. Cardiovasc Res. 2009;82:9-20.
35. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656-1662.
36. Youn JY, Siu KL, Li Q, Harrison DG, Cai H. Oxidase interactions in cardiovascular disease. In: Ismail LAHER, ed. Systems Biology of Free Radicals and Antioxidants. Berlin, Heidelberg: Springer; 2014:849-876.
37. Mayer B, Werner ER. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide. Naunyn Schmiedebergs Arch Pharmacol. 1995;351:453-463.
38. Chia KK, Liu CC, Hamilton EJ, Garcia A, Fry NA, Hannam W, Figtree GA, Rasmussen HH. Stimulation of the cardiac myocyte Na+-K+ pump due to reversal of its constitutive oxidative inhibition. Am J Physiol Cell Physiol. 2015;309:C239-C250.
39. White CN, Hamilton EJ, Garcia A, Wang D, Chia KKM, Figtree GA, Rasmussen HH. Opposing effects of coupled and uncoupled NOS activity on the Na+-K+ pump in cardiac myocytes. Am J Physiol Cell Physiol. 2008;294:C572-C578.
40. Figtree GA, Keyvan Karimi G, Liu CC, Rasmussen HH. Oxidative regulation of the Na(+)-K(+) pump in the cardiovascular system. Free Radic Biol Med. 2012;53:2263-2268.
41. Chen CA, De Pascali F, Basye A, Hemann C, Zweier JL. Redox modulation of endothelial nitric oxide synthase by glutaredoxin-1 through reversible oxidative post-translational modification. Biochemistry. 2013;52:6712-6723.
42. Knorr M, Hausding M, Kroller-Schuhmacher S, Steven S, Oelze M, Heeren T, Scholz A, Gori T, Wenzel P, Schulz E, Daiber A, Munzel T. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and Sglutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol. 2011;31:2223-2231.
43. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res. 2007;75:349-358.
44. Babior BM. The activity of leukocyte NADPH oxidase: regulation by p47PHOX cysteine and serine residues. Antioxid Redox Signal. 2002;4:35-38.
45. Feng MG, Prieto MC, Navar LG. Nebivolol-induced vasodilation of renal afferent arterioles involves beta3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol. 2012;303:F775-F782.
46. Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2-and beta3-adrenoceptors. Br J Pharmacol. 2010;160:1048-1061.
47. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144: 317-322.
48. Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ. Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-ethylphenoxy)-1-[(1, S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol. 2007;72:1359-1368.
49. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, Heeren T, Steven S, Hausding M, Knorr M, Pautz A, Reifenberg K, Schulz E, Gori T, Wenzel P, Munzel T, Daiber A. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes. 2011;60:2608-2616.
50. de Souza CJ, Burkey BF. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001;7:1433-1449.
51. Arch JR. Challenges in beta(3)-adrenoceptor agonist drug development. Ther Adv Endocrinol Metab. 2011;2:59-64.
52. Rasmussen HH, Figtree GA, Krum H, Bundgaard H. Treatment of heart failure with b3-receptor agonists. Curr Opin Investig Drugs. 2009;10:955-962.
53. Kulandavelu S, Hare JM. Alterations in beta3-adrenergic cardiac innervation and nitric oxide signaling in heart failure. J Am Coll Cardiol. 2012;59:1988-1990.
54. Fry NA, Garcia A, Karimi Galougahi K, Liu CC, Hamilton EJ, McLachlan CS, Figtree GA. Treatment with a beta3 adrenergic receptor agonist in heart failure reverses an oxidative modification and inhibition of the Na+-K+ pump in cardiac myocytes and improves pulmonary congestion. Circulation. 2013;128: A17142.
55. National Library of Medicine (US). Beta 3 agonist treatment in heart failure (Beat-HF) (Online). Available at: http://clinicaltrials.gov/show/NCT01876433. Accessed August 22, 2015.